for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BFRA.OQ

Latest Trade

14.00USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

11.05

 - 

18.22

As of on the NASDAQ Stock Exchange Capital Market ∙ Minimum 15 minute delay

Pricing

Previous Close
14.00
Open
--
Volume
--
3M AVG Volume
1.64
Today's High
--
Today's Low
--
52 Week High
18.22
52 Week Low
11.05
Shares Out (MIL)
44.82
Market Cap (MIL)
270.24
Forward P/E
-402.00
Dividend (Yield %)
--

Next Event

Q3 2019 Biofrontera AG Earnings Call

Latest Developments

More

Biofrontera Files Label Extension For Ameluz In EU To Include Treatment Of Actinic Keratosis On Extremities And Trunk/Neck

Biofrontera H1 Net Result Of EUR 8.6 Mln

Biofrontera Provides Update On Cutanea Integration

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.

Industry

Biotechnology & Drugs

Contact Info

Hemmelrather Weg 201

+49.null.214876320

https://biofrontera.com/

Executive Leadership

Ulrich Granzer

Chairman of the Supervisory Board

Hermann Luebbert

Chairman of the Management Board, Chief Executive Officer

Juergen Baumann

Vice Chairman of the Supervisory Board

Thomas Schaffer

Chief Financial Officer, Member of the Management Board

Christoph Duenwald

Member of the Management Board, Chief Commercial Officer

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-0.343

2017

-0.420

2018

-0.200

2019(E)

-0.015
Price To Earnings (TTM)
33.79
Price To Sales (TTM)
10.38
Price To Book (MRQ)
10.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
90.40
LT Debt To Equity (MRQ)
89.65
Return on Investment (TTM)
16.18
Return on Equity (TTM)
13.21

Latest News

BRIEF-Biofrontera Comments On Tender Offer By Deutsche Balaton

* Said on Thursday Comments On Tender Offer By Deutsche Balaton

BRIEF-Deutsche Balaton Biotech: Alternative Consideration To Offer For Biofrontera Shares

* SAID ON FRIDAY WITHIN THE OFFER FOR BIOFRONTERA SHARES, A WARRANT IS LISTED ON THE OPEN MARKET OF THE HANSEATIC STOCK EXCHANGE HAMBURG ON JULY 20, 2018 WITH 5.04 EUROS

BRIEF-Biofrontera: European Commission Approves Use Of Ameluz In Combination With Daylight Photodynamic Therapy

* PTA-ADHOC: BIOFRONTERA AG: EUROPEAN COMMISSION APPROVES USE OF AMELUZ IN COMBINATION WITH DAYLIGHT PHOTODYNAMIC THERAPY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biofrontera Closes $12.9 Million Firm Commitment IPO Of American Depositary Shares

* BIOFRONTERA AG ANNOUNCES CLOSING OF $US12.9 MILLION FIRM COMMITMENT INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biofrontera announces pricing of $12 mln firm commitment public offering of ADS & Nasdaq listing

* BIOFRONTERA AG ANNOUNCES PRICING OF US$12 MILLION FIRM COMMITMENT PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES AND NASDAQ LISTING

BRIEF-Biofrontera to Issue Up To 6 Mln New Shares Of EUR 1 Each

* SUBSCRIPTION PRICE FOR NEW SHARES WAS SET AT EUR 4.00 PER NEW SHARE ON FEBRUARY 9, 2018

BRIEF-Biofrontera Sets Price For New Shares At 4.00 Euros

* SUBSCRIPTION PRICE FOR NEW SHARES WAS SET TODAY AT EUR 4.00 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biofrontera AG Says Estimate That IPO Price Will Be Between $11 And $13 Per ADS

* BIOFRONTERA AG SAYS ESTIMATE THAT THE INITIAL PUBLIC OFFERING PRICE WILL BE BETWEEN $11.00 AND $13.00 PER ADS – SEC FILING

BRIEF-Biofrontera Adjusts Expectations With Regard To Subscription Price Of New Shares

* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA AG ADJUSTS EXPECTATIONS WITH REGARD TO SUBSCRIPTION PRICE OF NEW SHARES

BRIEF-Biofrontera Resolves On Capital Increase

* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA AG RESOLVES ON CAPITAL INCREASE

BRIEF-Biofrontera Receives Favorable CHMP Assessment For Ameluz In Combination With Daylight Photodynamic Therapy

* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA RECEIVES FAVORABLE CHMP ASSESSMENT FOR AMELUZ® IN COMBINATION WITH DAYLIGHT PHOTODYNAMIC THERAPY

BRIEF-Biofrontera AG Says Estimate That IPO Price Will Be Between $8.80 And $10.80 Per ADS

* BIOFRONTERA AG SAYS ESTIMATE THAT INITIAL PUBLIC OFFERING PRICE WILL BE BETWEEN $8.80 AND $10.80 PER ADS - SEC FILING Source text : (http://bit.ly/2DCrvYW) Further company coverage:

BRIEF-Biofrontera: 12-Month Follow-Up Results Of Phase III Trial For Daylight PDT

* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA RECEIVES 12-MONTH FOLLOW-UP RESULTS OF THE PHASE III TRIAL FOR DAYLIGHT PDT

BRIEF-Biofrontera AG Files For U.S. IPO Of Up To $21.6 Million

* BIOFRONTERA AG FILES FOR U.S. IPO OF UP TO $21.6 MILLION – SEC FILING

BRIEF-Biofrontera AG Says Intends To Offer ADS In Registered U.S. Offering Following A Listing On Nasdaq Capital Markets

* PTA-ADHOC: BIOFRONTERA AG: INTENTION TO OFFER AMERICAN DEPOSITARY SHARES IN REGISTERED U.S. OFFERING FOLLOWING A LISTING ON NASDAQ CAPITAL MARKETS Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )

BRIEF-Biofrontera Files Investigational New Drug Application

* PTA-NEWS: BIOFRONTERA AG: BIOFRONTERA FILES INVESTIGATIONAL NEW DRUG APPLICATION

BRIEF-Biofrontera 9-Mth ‍Net Loss Widens to EUR 14.6 Mln

* REVENUES INCREASED BY 155% TO EUR7.3 MILLION IN 9MTH, COMPARED TO EUR2.9 MILLION IN SAME PERIOD 2016

BRIEF-Biofrontera adjusts revenues and earnings forecast for FY 2017

* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA ADJUSTS REVENUES AND EARNINGS FORECAST FOR THE FINANCIAL YEAR 2017

BRIEF-Biofrontera: CMS issues new reimbursement codes for Ameluz

* PTA-NEWS: BIOFRONTERA AG: CMS ISSUES NEW REIMBURSEMENT CODES FOR AMELUZ® AND FOR PHOTODYNAMIC THERAPY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biofrontera achieves strong U.S. sales performance of Ameluz in first year

* PTA-NEWS: BIOFRONTERA AG: BIOFRONTERA ACHIEVES STRONG U.S. SALES PERFORMANCE OF AMELUZ® IN FIRST YEAR OF COMMERCIALIZATION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up